Leukemia & Lymphoma最新文献_第7页

Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old. calgb10403与HyperCVAD治疗≥40岁成人费城染色体阴性急性淋巴细胞白血病的比较

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-21 DOI: 10.1080/10428194.2025.2506003

Purav Mehta, Dat Ngo, Jose Tinajero, Vaibhav Agrawal, Paul Koller, Hoda Pourhassan, Shukaib Arslan, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss

引用次数: 0

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study. 卡非佐米联合R-CHOP初始治疗非生发中心弥漫性大b细胞淋巴瘤：一项多中心、单组、1/2期研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-21 DOI: 10.1080/10428194.2025.2504156

Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison M Winter, Wesam Ahmed, Mitchell Smith, Alex Mejia Garcia, Brenda Cooper, Ethan Krauspe, Jonathan Zhou, Taylor Brooks, Merve Kacar, Jenna Thomas, Hong Li, Xuefei Sophie Jia, Yanwen Chen, Paolo Caimi

{"title":"Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.","authors":"Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison M Winter, Wesam Ahmed, Mitchell Smith, Alex Mejia Garcia, Brenda Cooper, Ethan Krauspe, Jonathan Zhou, Taylor Brooks, Merve Kacar, Jenna Thomas, Hong Li, Xuefei Sophie Jia, Yanwen Chen, Paolo Caimi","doi":"10.1080/10428194.2025.2504156","DOIUrl":"10.1080/10428194.2025.2504156","url":null,"abstract":"We performed a phase I/II trial to explore the safety and efficacy of carfilzomib (K) in combination with R-CHOP (KR-CHOP) in patients with diffuse large B cell lymphoma (DLBCL). A total of 48 patients were enrolled and 47 were treated. The overall response rate (ORR) was 89% (70% complete response). At a median follow-up of 31 months, 3-year Kaplan-Meier estimates of PFS and OS were 79% and 87%, respectively. Treatment with KR-CHOP for non-GC DLBCL was associated with a decreased risk of disease progression and death relative to standard of care treatment with R-CHOP with hazard ratios (HR) of 0.16 [95% confidence interval (CI) 0.04-0.58, p = 0.002] and 0.31 [(95% CI, 0.09 - 0.99), p = 0.02], respectively. The most common grade 3 or 4 adverse events (AEs) were anemia (13%), thrombocytopenia (9%) and febrile neutropenia (9%). KR-CHOP is safe and may have preferential activity in non-GC DLBCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic stratification of standard risk multiple myeloma defined by revised international scoring system. 经修订的国际评分系统定义的标准危险多发性骨髓瘤的预后分层。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-20 DOI: 10.1080/10428194.2025.2504154

Gregorio Barilà, Laura Bonaldi, Annalisa Martines, Anna Pascarella, Susanna Vedovato, Cristina Clissa, Laura Pavan, Martina Tinelli, Silvia Nalio, Angela Bonalumi, Antonella Teramo, Giulia Calabretto, Gianpietro Semenzato, Livio Trentin, Mauro Krampera, Alberto Tosetto, Renato Zambello

引用次数: 0

A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type. 原发性皮肤弥漫性大B细胞淋巴瘤-腿型的发病机制及治疗现状。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-20 DOI: 10.1080/10428194.2025.2506503

Ewa Robak, Marcin Braun, Tadeusz Robak

{"title":"A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type.","authors":"Ewa Robak, Marcin Braun, Tadeusz Robak","doi":"10.1080/10428194.2025.2506503","DOIUrl":"https://doi.org/10.1080/10428194.2025.2506503","url":null,"abstract":"Primary cutaneous diffuse large B cell lymphoma, leg type (PCDLBCL-LT) is an aggressive B cell extranodal variant of lymphoma present in the skin, typically without evidence of extra cutaneous spread at the time of diagnosis. PCDLBCL-LT accounts for 20% of all primary cutaneous B cell lymphomas (CBCL) and 5% of all primary cutaneous lymphomas (PCL). It is more common in the elderly (median age 75 years). The disease commonly manifests as rapidly-growing red to bluish often ulcerating, nodular tumors, plaques or violaceous nodules on one or both lower extremities. Only 10% to 15% of lesions develop in other areas. A prognosis of PCDLBCL-LT is poor, with a 5-year survival rate of 40 to 50%. The first-line treatment of PCDLBCL-LT includes immunochemotherapy, most commonly R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone). In the case of a solitary lesion, excision or radiotherapy should be considered. Many patients demonstrate cutaneous relapses (70%) or systemic dissemination (50%). Recent studies have reported the use of Bruton's tyrosine-kinase (BTK) inhibitors, BCL2 inhibitors, immunomodulatory drugs and immune check-point inhibitors in treating relapsed or refractory patients. The study summarizes the current view of the pathogenesis, diagnosis and treatment of PCDLBCL-LT, including genetic abnormalities and novel targeted drugs.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia. AP2M1是急性髓系白血病中与细胞周期阻滞和肿瘤免疫微环境相关的预后标志物。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-19 DOI: 10.1080/10428194.2025.2504161

Ce Shi, Yang Li, Xing Zou, Dayong Yao, Jia Wei, Zhiyu Liu, Yue Su, Boqian Yu, Xin Zhang, Zhenkun Wang, Hui Liang, Hao Gang, Yanhong Zhao, Mengmeng Gu

引用次数: 0

Central nervous system relapse of core-binding factor acute myeloid leukemia. 核心结合因子急性髓系白血病的中枢神经系统复发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-19 DOI: 10.1080/10428194.2025.2506505

J Wesley Hill, Jennifer Marvin-Peek, Koji Sasaki, Sara Bresser, Bouthaina Shbib Dabaja, Nitin Jain, Gautam Borthakur, Hussein A Abbas

引用次数: 0

Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia. 改良的分期系统和IPSS与改良IPSS在亚洲单中心Waldenström巨球蛋白血症队列中的比较表现的证据。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-18 DOI: 10.1080/10428194.2025.2505705

Jia Chen, Jian Li, Dao-Bin Zhou, Xin-Xin Cao

{"title":"Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia.","authors":"Jia Chen, Jian Li, Dao-Bin Zhou, Xin-Xin Cao","doi":"10.1080/10428194.2025.2505705","DOIUrl":"https://doi.org/10.1080/10428194.2025.2505705","url":null,"abstract":"Waldenström macroglobulinemia (WM), a rare incurable low-grade B-cell lymphoma, exhibits heterogeneous survival outcomes. We evaluated the prognostic performance of a novel modified staging system of WM (MSS-WM) through comparison with existing models in a single-center cohort of 294 symptomatic WM patients. MSS-WM demonstrated significant stratification capacity (p < 0.0001), with 5-year overall survival rates of 89% (low-risk), 84% (low-intermediate), and 52% (intermediate/high-risk). All MSS-WM factors, including age, serum albumin, and LDH demonstrated independent prognostic impact. In addition, high beta-2 microglobulin level also showed negative prognostic impacts (p = 0.0002). While high concordance of MSS-WM and the revised IPSS (rIPSS-WM) was confirmed, the rIPSS-WM exhibited better predictive accuracy. However, MSS-WM's simplified structure enhances clinical utility, enabling rapid risk stratification: 89% 5-year survival in low-risk vs 52% in high-risk groups. This practical staging system requires no complex calculations, making it preferable for routine clinical implementation while maintaining comparable prognostic discrimination.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance. 与阿卡拉布替尼耐药性相关的CLL患者BTK C515残基的新分离突变

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-16 DOI: 10.1080/10428194.2025.2501269

Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kiriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis

引用次数: 0

Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment. 服用苯二氮卓类药物治疗naïve慢性淋巴细胞白血病患者与首次治疗时间较短有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-15 DOI: 10.1080/10428194.2025.2504155

Tamar Tadmor, Gal Lavie, Guy Melamed, Hilel Alapi, Lior Rokach

{"title":"Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.","authors":"Tamar Tadmor, Gal Lavie, Guy Melamed, Hilel Alapi, Lior Rokach","doi":"10.1080/10428194.2025.2504155","DOIUrl":"https://doi.org/10.1080/10428194.2025.2504155","url":null,"abstract":"Patients after diagnosis of leukemia face midlife crisis. In some instances, it may be accompanied by anxiety or depression, which may require pharmacological intervention. In this study, we explored the association between benzodiazepine (BZP) usage and time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL) under a watch-and-wait (W&W) approach. Utilizing data from Maccabi Healthcare Services in Israel, we analyzed 3,474 CLL patients, focusing on BZP and non-BZP users. 330 patients (9.5%) received a BZP agent for a minimum of 3 months. Among BZP users, the ten years treatment free ratio is 83.4%, while among non-BZP users it is 90.7%.Through inverse probability and time-dependent Cox proportional models, we observed that BZP usage was significantly associated with a shorter TTFT (HR 1.78, p = 0.029). Our study suggested BZP usage, is associated with shorter TTFT. While an association was observed, causality cannot be confirmed, and further studies are needed to validate the hypothetical association and clarify the underlying mechanisms and clinical implications.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera. 验证aaa模型（年龄，绝对中性粒细胞计数，绝对淋巴细胞计数）用于预测1000例真性红细胞增多症患者的生存和血栓形成。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-05-14 DOI: 10.1080/10428194.2025.2503458

Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak

{"title":"Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera.","authors":"Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak","doi":"10.1080/10428194.2025.2503458","DOIUrl":"https://doi.org/10.1080/10428194.2025.2503458","url":null,"abstract":"Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x109/L) absolute neutrophil and low(<1.7 × 109/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0